Press releases & Ad hoc News

New External Valuation Highlights Stability and Long-Term Value Potential of the Xlife Sciences AG Portfolio in the Valuation Report 2025

Xlife Sciences AG publishes 2025 Annual Report: Strategic positioning and preparation of key capital market transactions

Xlife Sciences AG Announces Exit of 12 Project Companies to Grupo Landsteiner and the Creation of a Scalable Transcontinental Life Sciences Platform

Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity

Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization

Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report

Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence

From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ

Xlife Sciences AG Announces Potential Acquisition of Portfolio Company FUSE-AI GmbH by Pineapple Power Corporation PLC at an Expected Valuation of EUR 80-90 million

Xlife Sciences AG Announces the Intended Listing of VERAXA Biotech AG on the NASDAQ Stock Exchange in the 2025 Fiscal Year

Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exchange in the First Half of 2025

Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)

Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and Solid Financial Figures

Xlife Sciences AG Completes Strategic Review Process by Q3 2024

Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report

Xlife Sciences AG Publishes 2023 Annual Report

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration

Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million

Xlife Sciences with significant progress in H1 2023

Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector

Xlife Sciences publishes agenda for Annual General Meeting 2023

Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential

Xlife Sciences publishes 2022 results and 2023 outlook

saniva diagnostics receives approval from the US FDA for its medical product NeuroMex

Xlife Sciences initiates a review of strategic options

Xlife Sciences with pleasing progress in the first half of 2022

Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario

Annual Report 2021 (only available in german)

License partner of Xlife Sciences announces successful completion of phase 1 of in-vivo trial for ATROSIMAB – out-licensing of the compound intended

Xlife Sciences: Date of publication Annual Report 2022

Laxxon Medical, a project company of Xlife Sciences, wins Evonik as investor and partner

Xlife Sciences' shares begin trading on SIX Swiss Exchange

Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange

Listing and first trading day on the “Sparks” segment of SIX Swiss Exchange expected for February 11, 2022

Xlife Sciences (XLS DE) plans listing on the “Sparks” segment of SIX Swiss Exchange

Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange

Partnership with Vision 2030

Xlife Sciences AG (XLS DE): Breakthrough in Drug Development

Xlife Sciences AG (XLS): 2020 financial results

Xlife Sciences AG (XLS): Antiviral drug candidate

Xlife Sciences AG: Transaction with Baliopharm AG

Xlife Sciences AG: Exit of a project company

Xlife Sciences AG: Xlife Sciences takes stake in palleos healthcare

Xlife Sciences AG: Active pharmaceutical ingredient for pneumonia caused by COVID-19 (coronavirus)

Xlife Sciences AG: Announcement of «Private Placement» capital increase (German only)

Xlife Sciences AG: Xlife Sciences AG issues convertible bond (German only)